Nat. Biotechnol. 34, 262–266; published online 10 March 2016; corrected after print 31 March 2016
In the version of this article initially published, the leadership of the team developing ADCs was incorrectly attributed, for which Nature Biotechnology takes full responsibility. To correct this, on p.265, paragraph 3, “Shen's team at Genentech” now reads “Jagath R. Junutula (then at Genentech, now at Cellerant Therapeutics in San Carlos, CA, USA) and colleagues”; on p.266, first line, “Since then, Shen's group” now reads, “Since then, Genentech”; and the photo of Shen with the caption, “Ben-Quan Shen's group at Genentech found a way to reduce the complexity of antibody-drug conjugates” has been replaced with a photo of Junutula with the caption, “Jagath R. Junutula's group highlighted the important role of site-specific conjugation in ADC development.” In addition, Kadcyla was misspelled as Kadcycla, and Adcetris as Adcentris. The errors have been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt.3509
Rights and permissions
About this article
Cite this article
Azvolinsky, A., Schmidt, C., Waltz, E. et al. Erratum: 20 years of Nature Biotechnology biomedical research. Nat Biotechnol 34, 666 (2016). https://doi.org/10.1038/nbt0616-666b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0616-666b
